17DD and 17D-213/77 Yellow Fever Substrains Trigger a Balanced Cytokine Profile in Primary Vaccinated Children

Background This study aimed to compare the cytokine-mediated immune response in children submitted to primary vaccination with the YF-17D-213/77 or YF-17DD yellow fever (YF) substrains. Methods A non-probabilistic sample of eighty healthy primary vaccinated (PV) children was selected on the basis of their previously known humoral immune response to the YF vaccines. The selected children were categorized according to their YF-neutralizing antibody titers (PRNT) and referred to as seroconverters (PV-PRNT+) or nonseroconverters (PV-PRNT−). Following revaccination with the YF-17DD, the PV-PRNT− children (YF-17D-213/77 and YF-17DD groups) seroconverted and were referred as RV-PRNT+. The cytokine-mediated immune response was investigated after short-term in vitro cultures of whole blood samples. The results are expressed as frequency of high cytokine producers, taking the global median of the cytokine index (YF-Ag/control) as the cut-off. Results The YF-17D-213/77 and the YF-17DD substrains triggered a balanced overall inflammatory/regulatory cytokine pattern in PV-PRNT+, with a slight predominance of IL-12 in YF-17DD vaccinees and a modest prevalence of IL-10 in YF-17D-213/77. Prominent frequency of neutrophil-derived TNF-α and neutrophils and monocyte-producing IL-12 were the major features of PV-PRNT+ in the YF-17DD, whereas relevant inflammatory response, mediated by IL-12+CD8+ T cells, was the hallmark of the YF-17D-213/77 vaccinees. Both substrains were able to elicit particular but relevant inflammatory events, regardless of the anti-YF PRNT antibody levels. PV-PRNT− children belonging to the YF-17DD arm presented gaps in the inflammatory cytokine signature, especially in terms of the innate immunity, whereas in the YF-17D-213/77 arm the most relevant gap was the deficiency of IL-12-producing CD8+T cells. Revaccination with YF-17DD prompted a balanced cytokine profile in YF-17DD nonresponders and a robust inflammatory profile in YF-17D-213/77 nonresponders. Conclusion Our findings demonstrated that, just like the YF-17DD reference vaccine, the YF-17D-213/77 seed lot induced a mixed pattern of inflammatory and regulatory cytokines, supporting its universal use for immunization.

[1]  C. Pannuti,et al.  Recent immunization against measles does not interfere with the sero-response to yellow fever vaccine. , 1999, Vaccine.

[2]  Bastian R. Angermann,et al.  Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses , 2008, The Journal of experimental medicine.

[3]  C. Rice,et al.  Complete nucleotide sequence of yellow fever virus vaccine strains 17DD and 17D-213. , 1995, Virus research.

[4]  D. Teuwen,et al.  Clinical and Immunological Insights on Severe, Adverse Neurotropic and Viscerotropic Disease following 17D Yellow Fever Vaccination , 2009, Clinical and Vaccine Immunology.

[5]  T. Monath,et al.  Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine. , 1981, Bulletin of the World Health Organization.

[6]  Eva K. Lee,et al.  Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans , 2009, Nature Immunology.

[7]  A. Teixeira-Carvalho,et al.  Innate immunity phenotypic features point toward simultaneous raise of activation and modulation events following 17DD live attenuated yellow fever first-time vaccination. , 2008, Vaccine.

[8]  Ana Carolina Campi-Azevedo,et al.  Cytokine signatures of innate and adaptive immunity in 17DD yellow fever vaccinated children and its association with the level of neutralizing antibody. , 2011, The Journal of infectious diseases.

[9]  R. Marchevsky,et al.  Molecular and phenotypic analysis of a working seed lot of yellow fever virus 17DD vaccine strain produced from the secondary seed lot 102/84 with an additional passage in chicken embryos. , 2006, Biologicals : journal of the International Association of Biological Standardization.

[10]  T. Monath,et al.  Randomized, double-blind, phase III, pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (Arilvax and YF-VAX) in healthy infants and children in Peru. , 2005, The American journal of tropical medicine and hygiene.

[11]  R. Henderson,et al.  Expanded programme on immunization. , 1988, World health statistics quarterly. Rapport trimestriel de statistiques sanitaires mondiales.

[12]  J. Fleiss.  The design and analysis of clinical experiments , 1987 .

[13]  L. Camacho,et al.  Reactogenicity of yellow fever vaccines in a randomized, placebo-controlled trial. , 2005, Revista de saude publica.

[14]  Joseph L. Fleiss,et al.  The Design and Analysis of Clinical Experiments: Fleiss/The Design , 1999 .

[15]  T. Monath,et al.  Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial. , 2002, The American journal of tropical medicine and hygiene.

[16]  B. Pulendran,et al.  Learning vaccinology from viral infections , 2011, The Journal of experimental medicine.

[17]  G. Deepe,et al.  Vaccine Immunity to Pathogenic Fungi Overcomes the Requirement for CD4 Help in Exogenous Antigen Presentation to CD8+ T Cells , 2003, The Journal of experimental medicine.

[18]  D. Golenbock,et al.  Beyond Empiricism: Informing Vaccine Development through Innate Immunity Research , 2012, Cell.

[19]  Randomized, double-blind, multicenter study of the immunogenicity and reactogenicity of 17DD and WHO 17D-213/77 yellow fever vaccines in children: implications for the Brazilian National Immunization Program. , 2007, Vaccine.

[20]  Á. L. Bertho,et al.  Detection of Th1/Th2 cytokine signatures in yellow fever 17DD first-time vaccinees through ELISpot assay. , 2008, Cytokine.

[21]  Bali Pulendran,et al.  Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity , 2006, The Journal of experimental medicine.

[22]  Bai,et al.  International Travel and Health , 1997 .

[23]  D. Teuwen,et al.  Immune response during adverse events after 17D-derived yellow fever vaccination in Europe. , 2008, The Journal of infectious diseases.

[24]  R. Galler,et al.  TLR expression and NK cell activation after human yellow fever vaccination. , 2009, Vaccine.

[25]  C. Rice,et al.  The Yellow Fever Virus Vaccine Induces a Broad and Polyfunctional Human Memory CD 8 T Cell Response 1 , 2009 .

[26]  E. Hindle,et al.  A YELLOW FEVER VACCINE , 1928, British medical journal.

[27]  M. Georges-Courbot,et al.  Thermostability and efficacy in the field of a new, stabilized yellow fever virus vaccine. , 1985, Vaccine.

[28]  P. Lambin,et al.  RESPONSE OF VOLTA CHILDREN TO JET INOCULATION OF COMBINED LIVE MEASLES, SMALLPOX AND YELLOW FEVER VACCINES. , 1964, Bulletin of the World Health Organization.

[29]  B. Fritzell,et al.  Study of combined vaccination against yellow fever and measles in infants from six to nine months. , 1989, Journal of Biological Standardization.

[30]  Luiz Antonio Bastos Camacho,et al.  Immunogenicity of WHO-17D and Brazilian 17DD yellow fever vaccines: a randomized trial. , 2004, Revista de saude publica.

[31]  A. Barrett,et al.  Yellow fever vaccine , 2005, Expert review of vaccines.